Patient characteristics | Â |
---|---|
Age (years), median [IQR25-75] | 53 (37–65) |
Female, n (%) | 840 (79.6%) |
AISD diagnosis, n (%) | Â |
 Lupus | 205 (19.4) |
 Sjögren | 190 (18) |
 Systemic sclerosis | 159 (15.1) |
 IM | 113 (10.7) |
 JIA | 110 (10.4) |
 Vasculitis | 94 (8.9) |
 Overlap syndrome | 84 (8.0) |
 Primary APS | 33 (3.1) |
 Sarcoidosis | 26 (2.5) |
 Behçet | 15 (1.4) |
 MCTD | 14 (1.3) |
 Other | 12 (1.2) |
Benefited from preventive work cessation, n (%) | 96/852 (11.3) |
At least one contact with a confirmed COVID-19 case, n (%) | 63/1054 (6.0) |
Self-suspected SARS-CoV-2 infection (according to the patient him/herself), n (%) | 201/1051 (19.1) |
Self-reported SARS-CoV-2 infection symptoms, n (%) | /1054 |
 Fever | 89 (8.4) |
 Chills | 62 (5.9) |
 Myalgia | 86 (8.2) |
 Cough/dyspnea | 133 (12.6) |
 Thoracic pain/oppression | 39 (3.9) |
 Gastroenteritis | 54 (5.1) |
 Anosmia | 42 (4.0) |
 Thrombosis | 1 (0.09) |
Risk factors for SARS-CoV-2 infection (history of), n (%) | /1054 |
 Cancer | 49 (4.6) |
 Cardiac failure | 34 (3.2) |
 Myocardial infarction | 29 (2.7) |
 Diabetes | 71 (6.7) |
 Hypertension | 250 (23.7) |
 Cerebrovascular event | 47 (4.5) |
 Respiratory failure | 126 (12.0) |
 Renal failure | 65 (6.2) |
 Hepatic insufficiency | 43 (4.1) |
BMI (kg/m2), median [IQR25-75] | 24.4 (21.2–28.7) |
 BMI > 35 | 53 (5.7) |
 BMI > 40 | 19 (2.1) |
Smoking status, n (%) | /973 |
 Current smoker | 129 (13.3) |
 Former smoker | 273 (28.1) |
 Never smoker | 571 (58.7) |
Treatments, n (%) | /1054 |
 NSAIDs | 81 (7.7) |
 Glucocorticoids | 289 (27.4) |
 Antimalarials (HCQ/CQ) | 262 (24.9) |
 Immunosuppressive agents/biologics | 447 (42.4) |
Treatment modification due to pandemic, n (%) | 73/1054 (6.9) |
Reporting a flare-up of AISD (self-diagnosed), n (%) | 166/1054 (15.7) |
Serological status for SARS-CoV-2, n (%) | Â |
 Positive IgG and/or IgM | 31/469 (6.6) |